Research progress on the impact of neoadjuvant immunotherapy on surgical treatment for non-small cell lung cancer
- VernacularTitle:新辅助免疫治疗对非小细胞肺癌外科治疗影响的研究进展
- Author:
Shuo LI
1
,
2
;
Guowei CHE
1
,
2
Author Information
1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
2. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Neoadjuvant immunotherapy;
time to surgery;
perioperative outcomes;
non-small cell lung cancer;
immune checkpoint inhibitors;
postoperative pulmonary complications
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(09):1457-1494
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the introduction of immune checkpoint inhibitors has significantly reshaped the therapeutic landscape for non-small cell lung cancer (NSCLC). Neoadjuvant immunotherapy (as monotherapy or in combination with chemotherapy) can significantly improve pathological response rates and has also demonstrated survival benefits when utilized within a comprehensive treatment regimen in combination with surgery. However, the tumor microenvironment remodeling induced by immunotherapy and immune-related adverse events present new challenges for surgical treatment strategies. This article addresses key issues in the surgical management of NSCLC in the context of neoadjuvant immunotherapy, focusing on three phases: preoperative, intraoperative, and postoperative, to explore the impact of immunotherapy on the selection of the time to surgery (TTS) and the optimal TTS, whether immunotherapy increases the difficulty and complexity of surgery, and whether immunotherapy affects the risk of perioperative complications. The aim is to provide guidance for surgical decision-making in clinical practice and to establish a foundation for future research directions.
